Thomas J. Hoerger, PhD; Russell Harris, MD, MPH; Katherine A. Hicks, MS; Katrina Donahue, MD, MPH; Stephen Sorensen, PhD; Michael Engelgau, MD
Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis. Ann Intern Med. 2004;140:689-699. doi: 10.7326/0003-4819-140-9-200405040-00008
Download citation file:
Published: Ann Intern Med. 2004;140(9):689-699.
*Diabetes onset; †Diabetes diagnosis by screening; ‡Diabetes diagnosed clinically.
The model is used to follow the disease progression of all members of a cohort simultaneously on 5 different disease paths. At the end of any period, the cohort occupies one state on each of the disease paths. For the simulation, transitions between states take place at discrete time intervals 1 year apart. Thus, at the end of each 1-year period, portions of the cohort can move from one disease state to another or stay in the same disease state. The simulation program determines what proportion of the cohort will move from one state to another on the basis of the transition probability. In several cases, an individual can experience a complication event that the patient either dies of or survives during the period. The Markov model keeps track of the number of patients who are in each state in each period. It also tracks the cumulative incidence of patients who have undergone complication events, such as lower-extremity amputation (LEA), angina, cardiac arrest (CA ) or myocardial infarction (MI), and stroke. In the diagrams, complication events are represented by diamonds; states are numbered and represented by ovals. CHD = coronary heart disease. ESRD = end-stage renal disease.
Appendix Table 1.
Appendix Table 2.
Appendix Table 3.
Appendix Table 4.
Appendix Table 5.
Appendix Table 6.
Appendix Table 7.
Appendix Table 8.
Appendix Table 9.
Appendix Table 10.
A probabilistic sensitivity analysis was conducted in which 129 critical parameters were simultaneously varied over probability distributions on the basis of published 95% CIs or other reasonable ranges. A cost-effectiveness ratio was computed for each of 1000 iterations for both targeted and universal screening of people age 55 years. QALY = quality-adjusted life-year.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Cardiology, Endocrine and Metabolism, Nephrology, Diabetes, Hypertension.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only